Sun Pharma and Philogen sign global licensing agreement for Fibromun
Agreement focuses on global commercialisation of anti-cancer immunotherapy
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Nidlegy
Sun Pharma, Philogen sign pact to commercialise specialty product, NIDLEGY in Europe, Australia and…
Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for…